Overview

JAK Inhibitor Dose TAPering Strategy Study

Status:
NOT_YET_RECRUITING
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose. Participants will: * Either take 1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms
Phase:
PHASE4
Details
Lead Sponsor:
University Hospital, Toulouse
Treatments:
baricitinib
GLPG0634
tofacitinib
upadacitinib